Treatment of early Parkinson's disease;Traitement d'une maladie de Parkinson debutante

Medecine Therapeutique

Volumn 3, Issue 3, 1997, Pages 202-206

  Broussolle, Emmanuel ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; LISURIDE MALEATE; PIRIBEDIL; SELEGILINE;

AGE; DRUG EFFICACY; DRUG INDICATION; FUTUROLOGY; HUMAN; PARKINSON DISEASE; REVIEW;

EID: 0030986758     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Hornykiewicz O., Kish S.J. 1986. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45 : 19-34.
2. Koller W.C. 1992. Initiating treatment in Parkinson's disease. Neurology 42 (suppl. 1) : 33-38.
3. Fahn S. 1974. « On-off » phenomenon with levodopa therapy in parkinsonism . clinical and pharmacological correlation and the effect of intramuscular pyridoxine. Neurology 24 : 431-441.
4. Nutt J.G., Holford N.H.G. 1996. The response to levodopa in Parkinson's disease : imposing pharmacological law and order. Ann Neurol 39 : 561-573.
5. Blin J.B., Bonnet A.M., Agid Y. 1988. Does levodopa aggravate Parkinson's disease ? Neurology 38 :1410-1416.
6. Rinne UK. 1990. Controlled-release levodopa superior to standard levodopa in the treatment of early Parkinson's disease. Mov Disord 5 (suppl. 1) : 52.
7. Montastruc J.L., Rascol O., Rascol A. 1990. Comparaison de la bromocriptine et de la lévodopa dans le traitement de première intention de la maladie de Parkinson . résultats à trois ans d'une étude prospective randomisée. Rev Neurol (Paris) 146 : 144-147.
8. Truelle J.L , Chanelet J., Bastard J., Six P , Emile J 1977. Le piribédil, agoniste dopaminergique. Étude clinique et électrophysiologique prolongée chez 60 parkinsoniens. Nouv Presse Med 6 : 2987-2990.
9. Montastruc J.L., Rascol O., Rascol A. 1989. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients : a 3 year follow-up study. J Neurol Neurosurg Psychiatry 52 : 773-775.
10. Bédard P.J., Dipaolo T., Falardeau P., Boucher R. 1986. Chronic treatment with levodopa, but not bromocriptine, induces dyskinesia in MPTP-Parkinsonian monkeys. Correlations with (3H) spiperone binding. Brain Res 379 : 294-299.
11. Giovannini P., Scogliano G., Piccolo I., Soliven P., Suchy I., Caraceni T. 1988. Lisuride in de novo Parkinsonian patients : a four-year follow-up. Acta Neurol Scand 77 : 322-327
12. Rinne U.K. 1987. Early combination of bromocriptine and levodopa in the treatment of Parkinson'disease : a five year follow-up. Neurology 37 : 826-828.
13. Rinne U.K. 1989 Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39 : 336-339.
14. Weiner W J., et al. 1993. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 43 . 21-27.
15. Montastruc J.L., Rascol O., Senard J.M , Rascol A. 1994. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up. J Neurol Neurosurg Psychiatry 57 : 1034-1038.
16. Langston J.W. Ballard P.A., Tetrud J.W., Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 : 979-980.
17. Heikkila R.E., Manzino L., Cabbat F S., Duvoisin R.C. 1984. Protection against the dopaminergic toxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 : 467-469.
18. Birkmayer W., Knoll J., Riederer P., Youdim M.B.H., Hars V., Marton J. 1985. Increased life expectancy resulting from addition of L-Deprenyl to Modopar treatment in Parkinson's disease : a longterm study. J Neural Transm 65 : 113-127
19. Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 . 1364-1371.
20. Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 : 176-183.
21. Lees A.J., and the PDRG of the United Kingdom. 1995. Comparison of therapeutic effect and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 311 : 1602-1607.
22. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. 1996. Br Med J 312 : 702-705.
23. Felten D.L , et al 1992. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 13 : 339-351.
24. Przuntek H., et al. 1992. Bromocriptine lessens the incidence of mortality in L-dopa treated parkinsonion patients : Prado-study discontinued. Eur J Clin Pharmacol 43 : 357-363.
25. Quinn N. 1995. Drug treatment of Parkinson's disease. Br Med J 310 : 575-579.
26. Olanow C.W., et al. 1994. A multicenter double blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease. Mov Disord 9 40-47.
27. Inzelberg R., et al. 1996. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 47 : 785-788.
28. Vidailhet M.J , Bonnet A.M., Belal S., Dubois B., Marie C., Agid Y. 1990. Ropinirole without levodopa in Parkinson's disease. Lancet 336 : 316-317.
29. Merello M., Lees A.J., Webster R., Bovingdon M., Gordin A. 1994. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57 : 186-189.
30. Roberts J.W., Cora-Locatelli G., Bravi D., Amantea M.A., Mourodian M.M., Chase T.N. 1994. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 44 : 2685-2688